Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâ€™s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Employees

1,402

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/03/26	79.45 $	+1.00%	2,503,118
03/03/26	78.66 $	-4.03%	2,045,143
02/03/26	81.96 $	+1.00%	3,098,359
27/02/26	81.15 $	+0.68%	2,773,689
26/02/26	80.60 $	-0.41%	3,330,043

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

79.45USD

Average target price

93.90USD

Spread / Average Target

+18.19%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 04/03/2026 GMT			5-day change	1st Jan Change
79.45 ^USD	+1.00%		-1.83%	+0.43%

03-02	Ionis Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
02-27	Ionis Pharmaceuticals, Inc. Announces to Present New Data Supporting Dawnzera (Donidalorsen) in Hereditary Angioedema At 2026 Aaaai Annual Meeting	CI

Capitalization	13.12B 11.29B 10.24B 9.82B 17.94B 1,210B 18.58B 120B 48.17B 577B 49.27B 48.21B 2,061B	P/E ratio 2026 *	-19.6x	P/E ratio 2027 *	-51.6x
Enterprise value	12.71B 10.93B 9.92B 9.51B 17.37B 1,172B 18B 117B 46.66B 559B 47.72B 46.7B 1,996B	EV / Sales 2026 *	15.4x	EV / Sales 2027 *	9.14x
Free-Float	99.23%	Yield 2026 *	-	Yield 2027 *	-

03-02	Ionis Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
02-27	Ionis Pharmaceuticals, Inc. Announces to Present New Data Supporting Dawnzera (Donidalorsen) in Hereditary Angioedema At 2026 Aaaai Annual Meeting	CI
02-26	Olezarsen sNDA accepted by the FDA for Priority Review	RE
02-26	Ionis Pharmaceuticals, Inc. Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference, Feb-26-2026 12:00 PM
02-26	Ionis Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Accepts for Priority Review the Supplemental New Drug Application for Olezarsen for Severe Hypertriglyceridemia	CI
02-26	GSK moves towards clearance of two new drugs in China and Japan	AN
02-25	Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-25	Ionis Pharmaceuticals, Inc., Q4 2025 Earnings Call, Feb 25, 2026
02-25	Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2026	CI
02-25	Ionis Pharmaceuticals' Q4 Net Loss Widens, Revenue Declines; 2026 Revenue Outlook Issued	MT
02-25	(IONS) Ionis Pharmaceuticals Expects Full Year 2026 Revenue Range $800M-$825M, vs. FactSet Est of $915M	MT
02-25	Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q4 Revenue $203M, vs. FactSet Est of $157.7M	MT
02-25	Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q4 Loss $1.41 a Share, vs. FactSet Est of $1.32 Loss	MT

12-17	RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
30/10/25	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
28/10/25	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
16/10/25	Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating	MT

Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Valuation: Ionis Pharmaceuticals, Inc.

Chart: Ionis Pharmaceuticals, Inc.

Latest news: Ionis Pharmaceuticals, Inc.

Last Transcript: Ionis Pharmaceuticals, Inc.

Analysts' recommendations: Ionis Pharmaceuticals, Inc.

Press Releases: Ionis Pharmaceuticals, Inc.

News in other languages: Ionis Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ionis Pharmaceuticals, Inc.

ETFs: Ionis Pharmaceuticals, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-02	Ionis to present new data supporting DAWNZERA in hereditary angioedema at 2026 AAAAI Annual Meeting	AQ
02-27	Ionis Pharmaceuticals : Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study	PU
02-27	Ionis Pharmaceuticals : Patient Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS HAE	PU
02-27	Ionis Pharmaceuticals : Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis	PU
02-27	Ionis Pharmaceuticals : Real world Adherence and Persistence with Long term Prophylaxis among Patients with Hereditary Angioedema	PU

01-07	Tratamiento contra hepatitis B crónica de GSK se muestra prometedor en estudios clave
30/10/25	Wall Street : Toujours debout, mais légèrement chancelant
24/10/25	BB Biotech profitiert von Erfolgen im Portfolio
08/10/25	Wall Street : En attente de signaux
03/09/25	Wall Street : Antitrust en recul, rendements en hausse

1 day	+1.00%
1 week	-1.83%
Current month	-2.09%
1 month	-6.52%
3 months	-2.88%
6 months	+33.87%
Current year	+0.43%

1 week	77.67	82.75
1 month	77.67	86.59
Current year	74.2	86.74
1 year	23.95	86.74
3 years	23.95	86.74
5 years	23.95	86.74
10 years	19.59	86.74

Manager	Title	Age	Since
D. Walke IRC	Investor Relations Contact	60	30/06/2012
Brett Monia CEO	Chief Executive Officer	64	31/12/2019
Elizabeth Hougen DFI	Director of Finance/CFO	64	30/04/2000

Director	Title	Age	Since
B. Parshall BRD	Director/Board Member	71	31/08/2000
Joseph Wender BRD	Director/Board Member	81	31/12/1993
Joseph Klein BRD	Director/Board Member	64	12/12/2005

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IONIS PHARMACEUTICALS, INC.	+1.00%	-1.83%	+141.12%	+117.08%	13.12B
LONZA GROUP AG	0.00%	-1.17%	-9.13%	-6.77%	47.3B
CELLTRION, INC.	-12.27%	-19.26%	+11.88%	+43.13%	29.54B
BEONE MEDICINES AG	+0.67%	-15.11%	+16.21%	+23.91%	33.17B
IQVIA HOLDINGS INC.	+2.25%	+9.86%	-3.10%	-19.45%	29.86B
REVOLUTION MEDICINES, INC.	+0.70%	-1.99%	+166.57%	+297.60%	20.05B
ASCENDIS PHARMA A/S	+0.90%	+5.87%	+60.06%	+111.51%	14.82B
EUROFINS SCIENTIFIC SE	-0.09%	-1.39%	+31.72%	+7.54%	13.72B
MEDPACE HOLDINGS, INC.	+0.10%	+6.34%	+43.61%	+133.17%	13.22B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+6.09%	-4.00%	+23,036.36%	+3,586.80%	12.58B
Average	-0.06%	-2.60%	+2,349.53%	+429.45%	22.74B
Weighted average by Cap.	-0.69%	-3.56%	+1,307.71%	+252.10%

	2026 *	2027 *
Net sales	828M 712M 646M 619M 1.13B 76.3B 1.17B 7.59B 3.04B 36.39B 3.11B 3.04B 130B	1.36B 1.17B 1.06B 1.02B 1.86B 126B 1.93B 12.5B 5.01B 59.95B 5.12B 5.01B 214B
Net income	-669M -575M -522M -501M -914M -61.67B -947M -6.13B -2.46B -29.41B -2.51B -2.46B -105B	-267M -229M -208M -200M -364M -24.58B -378M -2.44B -979M -11.72B -1B -979M -41.87B
Net Debt	-411M -353M -321M -308M -562M -37.88B -582M -3.77B -1.51B -18.07B -1.54B -1.51B -64.53B	-663M -570M -517M -496M -906M -61.09B -938M -6.07B -2.43B -29.13B -2.49B -2.43B -104B